In summary, patients with preexisting T1DM could be managed with insulin adjustment and use of usual care, including diabetes technology and insulin therapy, during ICI treatment without adverse outcomes related to glycemic control. The gene discussed is INS; the disease is type 1 diabetes mellitus.